Natural Killer (NK) Cell-based Strategies for Cancer Treatments

ISCT
6/28/21, 12:00 PM
Asia/Singapore +8

Description

About the Webinar

 

Join us as we hear from two Korean companies working to bring NK cell-based therapies to market. Both CAR-modified NK cells to treat malignant and recurrent blood cancers as well as combination therapy of NK cells and local immunogenic chemotherapy to treat hepatocellular carcinoma will be discussed. Don’t miss this opportunity to stay up to date in NK Cell therapy with a specific focus on the Asia market.

Learning Objectives:

  • Identify key considerations in the culture expansion of NK cells: medium, cell density, feeder layers, etc.
  • Discuss suitable potency assays to measure NK cell activity
  • Compare CAR-NK technology with adaptive NK & CAR T therapy
  • Combination strategies for NK-based therapies
  • Review possible solid tumor targets for combination NK or CAR-NK therapies
Previous registration necessary?

NO

YES
Simultaneous translation ?

NO

YES
Will it be recorded?
NO
YES

William YK Hwang

CAR Engineered NK cell as a novel immuno-oncology therapeutics, A Combinatorial NK Cell Therapy against Advanced Hepatocellular Carcinoma

Inglês

 

Speakers

Yu-Kyeong Hwang, Joon Haeng Rhee